Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns naming Muiris O’Connor .
Filed returns
141
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Rare Diseases Ireland | Health | Invitation to attend RDI's associated EU Presidency Event (Public policy or programme) | 21 | On lobbying.ie |
| May–Aug 2026 | Takeda Products Ireland | Health | Engagements on life-sciences policy, innovation and competitiveness in Ireland and Europe (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) | 27 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Life Science Strategy (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry perspectives on access, innovation and coordination. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Janssen Sciences Ireland UC | Health | Engagement with the Departments of Health and Enterprise regarding the national life science strategy (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Centric Health Primary Care Limited | Health | Background information on who Centric Health are and what they do (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Eli Lilly and Company | Health | Emerging trends in scientific research. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Eli Lilly and Company | Health | Emerging trends in scientific research. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | The Irish Clinical Oncology Group t/a Cancer Trials Ireland | Health | John O'Neill, PO at DOH gave a presentation at a CTI event on the upcoming Biotech Act pursuant to clinical trials. John O'Neill deputised for Muiris O'Connor (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | The Irish Clinical Oncology Group t/a Cancer Trials Ireland | Health | Sent letter to Asst Sec Muiris O'Connor DOH seeking his participation in a stakeholder meeting on March 20th concerning the upcoming Biotech Act (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Medicines Shortage - Provision in proposed EU General Pharmaceutical Legislation regarding medicines shortages prevention plan. (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry position on a National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | (i) IPHA priorities for EU Presidency and (ii) EU Presidency Events (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Takeda Products Ireland | Health | National Life Science Strategy engagements (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Dexcom | Health | Diabetes Policy in Ireland (Public policy or programme) | 43 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Rare Diseases Ireland | Health | Rare Diseases at the EU Presidency (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2025 | Rare Diseases Ireland | Health | Seeking to highlight rare diseases during Ireland's EU Presidency in 2026 with an official event during the presidency (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Janssen Sciences Ireland UC | Health | Engagement with the Department of Health on the Life Sciences Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Advocate for Life Science Strategy (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2025 | Rare Diseases Ireland | Health | Seeking to highlight rare diseases during Ireland's EU Presidency in 2026 with an official event during the presidency (Public policy or programme) | 35 | On lobbying.ie |
| May–Aug 2025 | Illumina Cambridge Ltd | Health | National Genomics Strategy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Ibec | Health | National Clinical Trials Office (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2025 | BearingPoint Ireland | Health | Sharing insights on international learnings of successful practices in health electronic data interchange and AI adoption. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2025 | Novo Nordisk Limited | Health | Engagement with Government, MEPs and public officials regarding the life-sciences sector in Ireland and the EU General Pharmaceutical Legislation (GPL) including two roundtable events. (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2025 | Alliance of Medicines for Ireland Company Limited by Guarantee | Health | Correspondence to relevant stakeholders regarding MFI event 'Digital Solutions for a Greener Industry'. (Public policy or programme) | 13 | On lobbying.ie |
| Jan–Apr 2025 | Adelaide Health Foundation | Health | CEO met with Mr Muiris O'Connor, asst Sec Gen Department of Health on the 10th March 2025 to discuss AHF research project recommendations. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Platform for Patients' Organisations, Science and Industry | Health | National developments/updates in relation to digital health, AI, health information management (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Think Research Corporation | Health | Communicate the benefits of mandatory incident management (medication error) reporting for pharmacies in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Platform for Patients' Organisations, Science and Industry | Health | The Use of Artificial Intelligence (AI) in Healthcare in Ireland (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2024 | The Irish Clinical Oncology Group t/a Cancer Trials Ireland | Health | GCIG - International gynaecological conference (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2024 | The Irish Clinical Oncology Group t/a Cancer Trials Ireland | Health | GCIG - International gynaecological conference (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs. (Legislation) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 15 | On lobbying.ie |
| Sep–Dec 2024 | Rare Diseases Ireland | Health | EU Pharma Legislation (Legislation) | 1 | On lobbying.ie |
| May–Aug 2024 | Abbvie Limited | Health | Meeting with officials from the Department of Health as part of a delegation from the US Chamber of Commerce, to discuss industry wide concerns in Ireland regarding the EU Commission’s proposals to revise the general… (Legislation) | 1 | On lobbying.ie |
| May–Aug 2024 | AstraZeneca Pharmaceuticals (Ireland) DAC | Health | Meeting to discuss the EU Pharmaceutical legislation and the digital healthcare ecosystem in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Dexcom | Health | Diabetes Policy in Ireland (Public policy or programme) | 50 | On lobbying.ie |
| May–Aug 2024 | Instinctif Partners Public Affairs Ireland | Health | Invitation to the Medicines for Europe 18th Legal Affairs Conference 10-11 June in Dublin (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Instinctif Partners Public Affairs Ireland | Health | Invitation to the annual Medicines for Europe 2024 conference: 12 - 13 June in Dublin (Public policy or programme) | 22 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation, particularly items relating to incentives/intellectual property rights; (ii) EU wide access to new medicines. (Legislation) | 10 | On lobbying.ie |
| May–Aug 2024 | Vulcan Consulting Limited | Health | Diabetes Policy in Ireland (Public policy or programme) | 11 | On lobbying.ie |
| May–Aug 2024 | MSD | Health | Meeting with officials from the Department of Health as part of a delegation from the US Chamber of Commerce, to discuss industry wide concerns in Ireland regarding the impact of some aspects of the EU Commission’s… (Legislation) | 1 | On lobbying.ie |
| May–Aug 2024 | Irish Platform for Patients' Organisations, Science and Industry | Health | IPPOSI pre-budget submission 2025 (Matters involving public funds) | 26 | On lobbying.ie |
| Jan–Apr 2024 | Irish Medical Organisation | Health | General Scheme of the Health Information and the European Health Data Space (Legislation) | 1 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 141 | 100.0% |